



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application Number : 10/715,417 Confirmation No.: 5850
Applicant : Eivind Per Thor STRATEN et al.
Filed : November 19, 2003
Title : SURVIVIN-DERIVED PEPTIDES AND USE THEREOF
TC/Art Unit : 1646
Examiner: : Unassigned

Docket No. : 60820.000004
Customer No. : 21967

Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, and in compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56, applicants are submitting herewith copies of the references listed on the attached Form PTO-SB/08A (modified) for consideration and to be made of record herein by the U.S. Patent and Trademark Office in the above-captioned application.

The subject application is a Continuation-in-Part Application of, and claims priority under 35 U.S.C. §120 to, U.S. Application No. 10/354,090, filed January 30, 2003, which claims benefit of Application No. 60/352,284, filed January 30, 2002. In accordance with 37 C.F.R. § 1.98(d), patent documents and published articles which were cited in the prior application are listed on the accompanying Form PTO-SB/08A, but copies of these documents are not enclosed as they were provided in the prior application. Copies will be forwarded at the request of the Examiner.

Applicants respectfully point out that the submission of the listed references in this Information Disclosure Statement is not an admission that they are prior art or that they are material to patentability of any claims of the application. Also, the submission of this Information Disclosure Statement is not an indication that a search has been made.


Consideration of the foregoing plus the prompt return of a copy of the enclosed Form SB/08A with the Examiner's initials in the left column in accordance with MPEP 609 are respectfully requested.

In accordance with 37 C.F.R. § 1.97(b), this Information Disclosure Statement is believed to be submitted prior to the mailing of a first Office Action on the merits. Therefore, it is respectfully submitted that no fee is required for consideration of this information. However, in the event any fee is deemed necessary, the Commissioner is authorized to charge the undersigned's Deposit Account No. 50-0206.

Respectfully submitted,

HUNTON & WILLIAMS LLP

Dated: August 24, 2004

By: 
Robert C. Lampe, III
Registration No. 51,914

Hunton & Williams LLP
Intellectual Property Department
1900 K Street, N.W.
Suite 1200
Washington, DC 20006
(202) 955-1500 (telephone)
(202) 778-2201 (facsimile)

RCL/sdw:dms


Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/715,417
Filing Date	November 19, 2003
First Named Inventor	Eivind Per Thor STRATEN et al.
Art Unit	1646
Examiner Name	Unassigned
Attorney Docket Number	60820.000004

Sheet 1 of 10



PATENT DOCUMENTS

*Examiner Initials	Cite No.	DOCUMENT NUMBER Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US- 6,245,523	06-12-2001	ALTIERI	

FOREIGN PATENT DOCUMENTS

*Examiner Initials	Cite No.	FOREIGN PATENT DOCUMENT		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
		Country Code:	Number - Kind Code (if known)				YES	NO
	2.	WO	92/20356	11-26-1992	BOON, T. et al			
	3.	WO	94/05304	03-17-1994	BOON-FALLEUR, T., et al			
	4.	WO	97/28816	08-14-1997	JAGER, E., et al			
	5.	WO	00/03693	01-27-2000	LEASON, H., et al.			

NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
	6.	VAN DEN EYNDE, B. J. et al., "Tumor antigens recognized by T lymphocytes", Int. J. Clin. Lab. Res., 27:81-86, 1997		
	7.	ROSENBERG, S. A., "Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens," J. Natl. Cancer Inst., 22;88: 1635-1644, 1996		

EXAMINER SIGNATURE

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number		10/715,417	
				Filing Date		November 19, 2003	
				First Named Inventor		Eivind Per Thor STRATEN et al.	
				Art Unit		1646	
				Examiner Name		Unassigned	
Sheet	2	of	10	Attorney Docket Number		60820.000004	

NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
	8.	MARCHAND, M. et al., "T. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MACE-3 and presented by HLA- A1," Int. J. Cancer, 80: 219-230, 1999		
	9.	BROSSART, P. et al., "W. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes," Cancer Res., 58: 732-736, 1998.		
	10.	BROSSART, P. et al., "Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies," Blood, 93:4309-4317, 1999		
	11.	VONDERHEIDE, R. et al., "The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes," Immunity, 10:673-679, 1999		
	12.	LACASSE, E. C. et al., "The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene, 17:3247-3259, 1998		
	13.	ALTIERI, D. C. et al., "Survivin apoptosis: an interloper between cell death and cell proliferation in cancer," Lab Invest, 79:1327-1333, 1999		
	14.	AMBROSINI, G. et al., "Induction of apoptosis and inhibition of cell proliferation by survivin, in human melanoma," J. Invest Dermatol., 113:1076-1081, 1999		
	15.	GROSSMAN, D. et al., "Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma," J. Invest Dermatol., 113: 1076-1081, 1999.		
	16.	GROSSMAN, D. et al., "Expression of the apoptosis inhibitor, survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line," Lab Invest, 79: 1121-1126, 1999		
	17.	ANDERSEN, M. H. et al., "An assay for peptide binding to HLA-Cw*0102," Tissue Antigens, 54:185-190, 1999		

EXAMINER SIGNATURE

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO				Application Number		10/715,417	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Filing Date		November 19, 2003	
				First Named Inventor		Eivind Per Thor STRATEN et al.	
				Art Unit		1646	
				Examiner Name		Unassigned	
Sheet	3	of	10	Attorney Docket Number		60820.000004	
NON-PATENT LITERATURE DOCUMENTS							
*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				TRANSLATION	
						YES	NO
	18.	ANDERSEN, M. H. et al., "Phosphorylated Peptides Can Be Transported by TAP Molecules, Presented by Class I MHC Molecules, and Recognized by Phosphopeptide-Specific CTL. J. Immunol., 163:3812-3188, 1999					
	19.	MCCUTCHEON, M. et al., "A sensitive ELISPOT assay to detect low-frequency human T lymphocytes," J. Immunol. Methods, 210:149-166, 1997					
	20.	PASS, H. A. et al., "Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay," Cancer J. Sci. Am., 4: 316-323, 1998					
	21.	BERKE, Z. et al., "Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules," Leukemia, 14:419-426, 2000					
	22.	FALK, K. et al., "Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules," Nature, 351:290-296, 1991					
	23.	CORNELISON, T. L., "Human papillomavirus genotype 16 vaccines for cervical cancer prophylaxis and treatment, Curr. Opin. Oncol., 12:466-473, 2000					
	24.	LEE, S. P. et al., "CTL control of EVB in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells," Immunol., 165: 573-582, 2000					
	25.	SWANA, H. S. et al., "Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N. Engl. J. Med., 341: 452-453, 1999					
	26.	SALGALLER, M. L. et al., "Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res., 55: 4972-4979, 1995					
EXAMINER SIGNATURE				DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number		10/715,417	
				Filing Date		November 19, 2003	
				First Named Inventor		Eivind Per Thor STRATEN et al.	
				Art Unit		1646	
				Examiner Name		Unassigned	
Sheet	4	of	10	Attorney Docket Number		60820.000004	

NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
	27.	SALGALLER, H. L. et. al., "Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptide," Cancer Res., 56:4749-4757, 1996		
	28.	VALMORI, D. et al., "Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J. Immunol., 160: 1750-1758, 1998		
	29.	PARDOLL, D. H., "Cancer vaccines," Nat. Med., 4:525-531, 1998		
	30.	KUGLER, A. et al., "Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids," Nat. Med., 6:332-336, 2000		
	31.	BECKER, J. et al., "Accumulation of identical T cells in melanoma and vitiligo-like leukoderma," J. Invest. Dermatol., 113: 1033-1038, 1999		
	32.	ROHAYEM, J. et al., "Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients," Cancer Res., 2000, Apr., 1:60; (7.):1815-7., 60: 1815-1817		
	33.	ADIDA, C. et al., "Prognostic significance of survivin expression in diffuse large B-cell lymphomas," Blood, 96: 1921-1925, 2000		
	34.	ISLAM, A. et al., "High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma," Oncogene, 19:617-623, 2000		
	35.	KAWASAKI, H., "Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer," Cancer Res., 58:5071-5074, 1998		
	36.	SCHMITZ, M. et al., "Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides," Cancer Res., 60:4845-4849, 2000		

EXAMINER SIGNATURE

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number 10/715,417	
				Filing Date November 19, 2003	
				First Named Inventor Eivind Per Thor STRATEN et al.	
				Art Unit 1646	
				Examiner Name Unassigned	
Sheet	5	of	10	Attorney Docket Number 60820.000004	
NON-PATENT LITERATURE DOCUMENTS					
*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION		
			YES	NO	
	37.	ANDERSEN, M. H. et al., "Identification of a Cytotoxic T Lymphocyte Response to the Apoptosis inhibitor Protein Survivin in Cancer Patients," Cancer Res., 61:869-872, 2001			
	38.	LEE, K. H. et al., "Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination," J. Immunol., 161: 4183-4194, 1998			
	39.	ROSENBERG, S. A. et al., "Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma," Nat. Med., 4: 321-327, 1998			
	40.	ALTMAN, J. D. et al., "Phenotypic analysis of antigen-specific T lymphocytes," Science, 274: 94-96, 1996			
	41.	SCHRAMA, D. et al., "Oligoclonal I-Cell Receptor Usage Of Melanocyte Differentiation Antigen-reactive I Cells in Stage IV Melanoma Patients," Cancer Res., 61: 493-496, 2001			
	42.	LUXEMBOURG, A. T. et al., "Biomagnetic isolation of antigen-specific CCD8+ T cells usable in immunotherapy," Nat. Biotechnol., 16: 281-285, 1998			
	43.	KIRKIN, A. F. et al., "Generation of human-melanoma specific T lymphocyte clones defining novel cytolytic targets with panels of newly established melanoma cell lines," Cancer Immunol. Immunother., 41: 71-81, 1995			
	44.	SCHEIBENBOGEN, C. et al., "A sensitive ELISPOT assay for detection of CD8+T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients," Clin. Cancer Res., 3: 221-226, 1997			
EXAMINER SIGNATURE				DATE CONSIDERED	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

Substitute for form 1449A/PTO <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;"><i>(use as many sheets as necessary)</i></p>				Application Number 10/715,417		Filing Date November 19, 2003	
				First Named Inventor Eivind Per Thor STRATEN et al.			
				Art Unit 1646			
				Examiner Name Unassigned			
Sheet	6	of	10	Attorney Docket Number 60820.000004			

NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
	45.	thor STRATEN, P. et al., "In Situ I-Cell Responses against Melanoma Comprise High Numbers of Locally Expanded I-Cell Clonotypes," J. Immunol., 163: 443-447, 1999		
	46.	KESSLER, J. H. et al., "Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes In the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis," J. Exp. Med., 193: 73-88, 2001		
	47.	de VRIES, T. 3., Fourkour, A., Wobbes, I., Verkroost, G., Ruiter, D. 3., and van Muijen, C. N. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-I, and tyrosinase in human melanoma cell lines and in human melanocytic lesions," Cancer Res., 57: 3223-3229, 1997		
	48.	JAGER, E. et al., "Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo," Int. J. Cancer, 66: 470-476, 1996		
	49.	CORMIER, J. N. et al., "Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy," J. Immunother., 21: 27-31, 1998		
	50.	RIKER, A. et al., "Immune selection after antigen-specific immunotherapy of melanoma," Surgery, 126: 112-120, 1999		
	51.	MAEURER, N. J., "Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen," J. Clin. Invest, 98: 1633-1641, 1996		
	52.	GROSSMAN, D. et al., "Inhibition of melanoma tumor growth in vivo by survivin targeting.," Proc Natl. Acad. Sci. USA, 98: 635-640, 2001		
	53.	TAMM, I. et al., "IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs," Cancer Res., 58: 5315-5320, 1998		

EXAMINER SIGNATURE	DATE CONSIDERED
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/715,417
Filing Date	November 19, 2003
First Named Inventor	Eivind Per Thor STRATEN et al.
Art Unit	1646
Examiner Name	Unassigned

Sheet	7	of	10	Attorney Docket Number	60820.000004
-------	---	----	----	------------------------	--------------

NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
	54.	MONZO, M. et al., "A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers," J. Clin. Oncol., 17: 2100-2104, 1999		
	55.	NAKAGAWARA, A., "Molecular basis of spontaneous regression of neuroblastoma: role of neurotrophic signals and genetic abnormalities," Hum. Cell, 11: 115-124, 1998		
	56.	RENKVIST, N. et al., "A listing of human tumor antigens recognized by T cells," Cancer Immunol Immunother., 50: 3-15, 2001		
	57.	MELIEF, C. J. et al., "Strategies for immunotherapy of cancer," Adv. Immunol., 75:235-82.: 235-282, 2000		
	58.	GILBOA, E., "The makings of a tumor rejection antigen.," Immunity., 11: 263-270, 1999		
	59.	LI, F. et al., "Control of apoptosis and mitotic spindle checkpoint by survivin," Nature, 396: 580-584, 1998		
	60.	ZAFFARONI, N. et al., "Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions," Drug Resist. Updat., 5: 65-72, 2002		
	61.	SHINOZAWA, I. et al., "Disturbed expression of the anti-apoptosis gene, survivin, and EPR-1 in hematological malignancies," Leuk. Res, 24: 965-970, 2000		
	62.	GRANZIERO, L. et al., "Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia," Blood, 97: 2777-2783, 2001		
	63.	AMBROSINI, C. et al., "A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma," Nat. Med., 3: 917-921, 1997		

EXAMINER SIGNATURE

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Substitute for form 1449A/PTO			
				Application Number		10/715,417	
				Filing Date		November 19, 2003	
				First Named Inventor		Eivind Per Thor STRATEN et al.	
				Art Unit		1646	
Examiner Name		Unassigned					
Sheet	8	of	10	Attorney Docket Number		60820.000004	
NON-PATENT LITERATURE DOCUMENTS							
*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION				
			YES	NO			
	64.	ALTIERI, D. C. et al., "Validating survivin as a cancer therapeutic target," Nat. Rev. Cancer, 3: 46-54, 2003					
	65.	OLIE, R. A. et al., "A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy," Cancer Res, 60: 2805-2809, 2000					
	66.	ANDERSEN, N. H. et al., "Survivin--a universal tumor antigen," Histol. Histopathol., 17: 669-675, 2002					
	67.	ANDERSEN, N. H. et al., "Spontaneous cytotoxic I-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients," Cancer Res, 61: 5964-5968, 2001					
	68.	CURRIER, J. R. et al., "A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays," J. Immunol. Methods, 260: 157-172, 2002					
	69.	ELVIN, J., Potter, C., Elliott, I., Cerundolo, V., and Townsend, A., "A method to quantify binding of unlabeled peptides to class I MHC molecules and detect their allele specificity," J. Immunol Methods, 158: 161-171, 1993					
	70.	RUPPERT, J., Sidney, J., Celis, F., Kubo, R. I, Grey, H. N., and Sette, A., "Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules," Cell, 74: 929-937, 1993					
	71.	thor STRATEN, P., Barbed, A., Seremet, I., Saeterdal, I., Zeuthen, 3., and Guldberg, P. Detection and characterization of alpha-beta-T-cell clonality by denaturing gradient gel electrophoresis (DCGE).," Biotechniques, 25: 244-250,1998					
	72.	RAMMENSEE, H., Bachmann, J., Emmerich, N. P., Bachor, O. A., and Stevanovic, S., " SYFPEITHI: database for MHC ligands and peptide motifs," Immunogenetics, 50: 213-219, 1999					
EXAMINER SIGNATURE				DATE CONSIDERED			
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>							

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/715,417
Filing Date	November 19, 2003
First Named Inventor	Eivind Per Thor STRATEN et al.
Art Unit	1646
Examiner Name	Unassigned
Attorney Docket Number	60820.000004

Sheet **9** of **10**

NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
	73.	SCHRAMA, D., Pedersen Ls, L. O., Keikavoussi, P., Andersen, N. H., Straten, P. P., Brocker, E. B., Kampgen, F., and Brocker, E. C., "Aggregation of antigen-specific I cells at the inoculation site of mature dendritic cells," J. Invest Dermatol., 119: 1443-1448, 2002		
	74.	MAHOTKA, C., Wenzel, N., Springer, F., Gabbert, H. E., and Gerharz, C. D., "Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties," Cancer Res., 59: 6097-6102, 1999		
	75.	HICKLIN, D. J., Marincola, F. N., and Ferrone, S. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story," Mol. Med. Today, 5: 178-186, 1999		
	76.	SELIGER, B., Cabrera, T., Garrido, F., and Ferrone, S. HLA class I antigen abnormalities and immune escape by malignant cells," Semin. Cancer Biol., 12: 3-13, 2002		
	77.	SETTE, A., Vitiello, A., Rehman, B., Fowler, P., Nayersina, R., Kast, W. N., Melief, C. J., Oseroff, C., Yuan, F., and Ruppert, J., "The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes," J. Immunol., 153: 5586-5592, 1994		
	78.	MOUDGIL, K. D. and Sercarz, E. E., "Can antitumor immune responses discriminate between self and nonself?," Immunol. Today, 15: 353-355, 1994		
	79.	PARKHURST, M. R., Salgaller, N. L., Southwood, S., Robbins, P. F., Sette, A., Rosenberg, S. A., and Kawakami, Y., "Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues," J. Immunol., 157: 2539-2548, 1996		
	80.	GUICHARD, C., Zerbib, A., Le Gal, F. A., Hoebeke, J., Connan, F., Choppin, J., Briand, J. P., and Guillet, J. G., "Melanoma peptide MART-1(27-35) analogues with enhanced binding capacity to the human class I histocompatibility molecule HLA-A2 by introduction of a beta-amino acid residue: implications for recognition by tumor-infiltrating lymphocytes," J. Med. Chem., 43: 3803-3808, 2000		

EXAMINER SIGNATURE

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number 10/715,417	
				Filing Date November 19, 2003	
				First Named Inventor Eivind Per Thor STRATEN et al.	
				Art Unit 1646	
				Examiner Name Unassigned	
Sheet 10		of 10		Attorney Docket Number 60820.000004	
NON-PATENT LITERATURE DOCUMENTS					
*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION		
			YES	NO	
	81.	CLAY, T. M., Custer, M. C., McKee, M. D., Parkhurst, N., Robbins, P. F., Kerstann, K., Wunderlich, J., Rosenberg, S. A., and Nishimura, M. I., "Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue," J. Immunol., 162: 1749-1755, 1999			
	82.	MELIEF, C. J., van der Burg, S. H., Toes, R. E., Ossendorp, F., and Offringa, R., "Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Immunol. Rev., 188: 177-182, 2002			
	83.	JAGER, E., Ringhoffer, M., Altmannsberger, M., Arand, M., Karbach, J., Jager, D., Oesch, F., and Knuth, A., "Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma," Int. J. Cancer, 71: 142-147, 1997			
	84.	THURNER, B., Haendle, I., Roder, C., Dieckmann, D., Keikavoussi, P., Jonuleit, H., Bender, A., Maczek, C., Schreiner, D., von den, D. P., Brocker, E. B., Steinman, R. M., Enk, A., Kämpgen, E., and Schuler, G., "Vaccination with mage3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma," J. Exp. Med., 190: 1669-1678, 1999			
	85.	YEE, C., Thompson, J. A., Roche, P., Byrd, D. P., Lee, P. P., Piepkorn, N., Kenyon, K., Davis, N. N., Riddell, S. R., and Greenberg, P. D., "Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of cell-mediated vitiligo," J. Exp. Med., 192: 1637-1644, 2000			
	86.	SIMON, R. M., Steinberg, S. M., Hamilton, M., Hildesheim, A., Khleif, S., Kwak, L. W., Mackall, C. L., Schlom, J., Topalian, S. L., and Berzofsky, J. A., "Clinical trial designs for the early clinical development of therapeutic cancer vaccines," J. Clin. Oncol., 19: 1848-1854, 2001			
EXAMINER SIGNATURE			DATE CONSIDERED		
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>					